webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

MC-Val-Cit-PAB-dimethylDNA31

  CAS No.: 1639352-06-9   Cat No.: BADC-01470 4.5  

MC-Val-Cit-PAB-dimethylDNA31 has a bioreversible linkage based on a quaternary ammonium for targeted delivery and it can improve pharmacokinetics and the therapeutic index. MC-Val-Cit-PAB-dimethylDNA31 is used for the antibody-drug conjugates (ADC) that are effective and stable in vitro and in vivo to treat various diseases or disorders.

MC-Val-Cit-PAB-dimethylDNA31

Structure of 1639352-06-9

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C78H101N10O19
Molecular Weight
1482.69

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
MC-Val-Cit-PAB-dimethylDNA31
IUPAC Name
[1-[(7S,9Z,11S,12R,13S,14R,15R,16R,17S,18S,19E,21E)-13-acetyloxy-2,6,15,17-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-23,32,37-trioxo-8,27,38-trioxa-24,34-diazahexacyclo[23.11.1.14,7.05,36.026,35.028,33]octatriaconta-1,3,5,9,19,21,25,28,30,33,35-undecaen-30-yl]piperidin-4-yl]-[[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrol-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl]-dimethylazanium
Canonical SMILES
CC1C=CC=C(C(=O)NC2=C3C(=C4C(=C(C(=C5C4=C(C(O5)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)O)C)O)C2=O)N=C6C(=CC(=CC6=O)N7CCC(CC7)[N+](C)(C)CC8=CC=C(C=C8)NC(=O)C(CCCNC(=O)N)NC(=O)C(C(C)C)NC(=O)CCCCCN9C(=O)C=CC9=O)O3)C
InChI
InChI=1S/C78H100N10O19/c1-40(2)62(83-56(91)22-15-14-16-33-87-57(92)27-28-58(87)93)76(101)82-52(21-18-32-80-77(79)102)75(100)81-49-25-23-48(24-26-49)39-88(11,12)51-29-34-86(35-30-51)50-37-53(90)63-55(38-50)106-72-64(84-63)59-60-68(96)46(8)71-61(59)73(98)78(10,107-71)104-36-31-54(103-13)43(5)70(105-47(9)89)45(7)67(95)44(6)66(94)41(3)19-17-20-42(4)74(99)85-65(72)69(60)97/h17,19-20,23-28,31,36-38,40-41,43-45,51-52,54,62,66-67,70,94-95H,14-16,18,21-22,29-30,32-35,39H2,1-13H3,(H8-,79,80,81,82,83,84,85,90,91,92,93,96,97,98,99,100,101,102)/p+1/b19-17+,36-31-,42-20+/t41-,43+,44+,45+,52-,54-,62-,66-,67+,70+,78-/m0/s1
InChIKey
ZPRVTBDKPIFAGV-SVJSIQBQSA-O

MC-Val-Cit-PAB-dimethylDNA31 is a specialized conjugate designed to deliver the potent nucleic acid-modifying agent dimethylDNA31 to specific cellular targets. DimethylDNA31, a modified DNA analog, has been studied for its ability to modulate gene expression and interfere with cellular processes by interacting with the DNA. By linking dimethylDNA31 to a peptide through the MC-Val-Cit-PAB linker, this conjugate facilitates the targeted delivery of the DNA-modifying agent to cells or tissues that express specific biomarkers, improving the therapeutic efficacy while minimizing side effects. This approach opens up new possibilities for targeted genetic therapies and gene regulation.

One of the key applications of MC-Val-Cit-PAB-dimethylDNA31 is in gene therapy, where it can be used to deliver genetic regulators directly to specific tissues or cells. Traditional gene therapy approaches often suffer from low specificity and off-target effects, which can lead to unwanted consequences in healthy tissues. The MC-Val-Cit-PAB linker in this conjugate enables the selective targeting of cells or tissues expressing particular receptors or biomarkers, ensuring that dimethylDNA31 is delivered directly to the desired site. This enhances the precision of genetic interventions, improving the outcomes of gene therapy while reducing potential side effects.

MC-Val-Cit-PAB-dimethylDNA31 also has potential applications in cancer therapy, especially in cancers where specific genetic mutations or overexpressed proteins drive tumorigenesis. By attaching dimethylDNA31 to a targeting peptide, the conjugate can deliver the DNA-modifying agent specifically to cancer cells that overexpress certain receptors. Once inside the tumor cells, dimethylDNA31 can modify the DNA or influence gene expression, potentially disrupting key oncogenic pathways. This targeted approach may offer a more effective and less toxic alternative to conventional cancer therapies.

In addition to gene and cancer therapies, MC-Val-Cit-PAB-dimethylDNA31 could be useful in drug discovery and research. By selectively delivering dimethylDNA31 to specific cell types or tissues, researchers can study its effects on gene expression, DNA repair mechanisms, and cellular processes. This conjugate could serve as a tool for investigating the roles of specific genes in various biological functions, as well as for screening potential drug candidates that can modulate DNA-related pathways. Its ability to target precise cellular locations allows for more controlled experimental conditions and more accurate results in research settings.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records: Triptolide | Fmoc-N-amido-PEG3-propionic acid | N-(2-(2-Fluorophenoxy)ethyl)-4-Formylbenzamide | Modified MMAF-C5-COOH | MC-Ala-Ala-Asn-PAB | D-Val-L-Cit-PAB | Boc-NH-PEG3-C2-triazole-DBCO-PEG4-VC-PAB-DMEA | Eribulin Mesylate | perfluorophenyl 3-(pyridin-2-yldisulfanyl)propanoate | Acid-PEG2-SS-PEG2-acid | MC-Val-Cit-PAB-dimethylDNA31
Send Inquiry
Verification code
Inquiry Basket